title: Long-term tolerability of etoricoxib in different types of NSAID-intolerant subjects.
abstract: BACKGROUND
  Non-steroidal anti-inflammatory drugs (NSAIDs) are a frequent cause of hypersensitivity reactions, therefore, in clinical practice, it's important to find safe and effective substances.
  
  
  OBJECTIVE
  To evaluate the tolerability of etoricoxib and its subsequent actual use and safety at home.
  
  
  METHODS
  Etoricoxib tolerance was assessed by single-blind-placebo-controlled oral challenges and its subsequent use was checked by a standardized telephone call. The test was performed in 139 subjects (83 single NSAID reactors and 56 multiple NSAID reactors).
  
  
  RESULTS
  The drug was not tolerated in 4 cases (2.8%) causing wheals on the face area in 3 single reactors and a severe generalised reaction occurring three hours after the intake of a therapeutic dose in a multiple reactor. The phone calls showed that 64 (52.8%) patients did not take etoricoxib, mostly due to the fear of adverse effects; in 5 cases (4.2%), the practitioner prescribed a different NSAIDs. Only 52 (43%) subjects took etoricoxib after oral challenges; all tolerated the drug but 2 single reactors, who reported a very mild labial oedema.
  
  
  CONCLUSIONS
  Our study confirmed the good long-term tolerability of etoricoxib in patients with a history of hypersensitivity to other NSAIDs without differences between single and multiple reactors. Nonetheless, in NSAID-intolerant subjects this drug should be first challenged in specialised centres due to the risk ofsevere reactions.
authors.affiliation: Servizio di Allergologia e Oncologia, Ospedale Civile di Asola, Dipartimento di Medicina, Azienda Ospedaliera C. Poma Mantova. mauro.pagani@aopoma.it
authors.forename: M
authors.initials: M
authors.lastname: Pagani
authors.forename: P
authors.initials: P
authors.lastname: Bonadonna
authors.forename: A
authors.initials: A
authors.lastname: Dama
authors.forename: G E
authors.initials: GE
authors.lastname: Senna
authors.forename: P P
authors.initials: PP
authors.lastname: Vescovi
authors.forename: A
authors.initials: A
authors.lastname: Antico
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects*; D004342:Drug Hypersensitivity / Q000209:etiology*; D000077613:Etoricoxib; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011725:Pyridines / Q000009:adverse effects*; D016037:Single-Blind Method; D013450:Sulfones / Q000009:adverse effects*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D052246:Cyclooxygenase 2 Inhibitors; D011725:Pyridines; D013450:Sulfones; D000077613:Etoricoxib